Heparin in malignant glioma: review of preclinical studies and clinical results

Journal of Neuro-Oncology

Volumn 124, Issue 2, 2015, Pages 151-156

  Schnoor, Rosalie ^a   Maas, Sybren L N ^a   Broekman, Marike L D ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Glioblastoma multiforme; Glioma; Heparin; Low molecular weight heparin

Indexed keywords

ACLARUBICIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW DENSITY LIPOPROTEIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NECUPARANIB; PARVOVIRUS VECTOR; PLACEBO; SEMAXANIB; TEMOZOLOMIDE; TINZAPARIN; ANTINEOPLASTIC AGENT;

ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; BLEEDING; BREAST CARCINOMA; CANCER INHIBITION; CHEMICAL MODIFICATION; CONTROLLED CLINICAL TRIAL (TOPIC); DEEP VEIN THROMBOSIS; DRUG CHOICE; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; EXOSOME; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; NEUROSURGERY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PHARMACODYNAMICS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SOLID TUMOR; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT DURATION; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BRAIN NEOPLASMS; GLIOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GLIOMA; HEPARIN; HUMANS;

EID: 84942501695     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1826-x     Document Type: Review

References (60)

1. Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466
2. Green D, Hull R, Brant R, Pineo G (1992) Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin [letter]. Lancet 339(8807):1476
3. Prandoni P, Lensing AW, Büller HR, Carta M, Cogo A, Vigo M et al (1992) Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339(8791):441–445
4. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG et al (1992) Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 326(15):975–982
5. Lee A, Levine M, Baker R, Bowden C, Kakkar A, Prins M, Rickles F, Julian J, Math M, Haley S, Kovacs M, Gent M (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153
6. Akl E, Gunukula S, Barba M, Ved Y, Van Doormaal F, Kuipers S, et al (2013) Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation (Review). Cochrane database Syst Rev 4:CD006652
7. Zacharski LR (2008) Heparin as an anticancer therapeutic. Expert Opin Investig Drugs 17(7):1029–1037
8. EL Andaloussi S, Mäger I, Breakefield XO, Wood MJ (2013) Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 12(5):347–357
9. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M et al (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10(12):1470–1476
10. Atai NA, Balaj L, van Veen H, Breakefield XO, Jarzyna PA, Van Noorden CJF et al (2013) Heparin blocks transfer of extracellular vesicles between donor and recipient cells. J Neurooncol 115(3):343–351
11. Zacharski LR, Ornstein DL (1998) Heparin and cancer. Thromb Haemost 80(1):10–23
12. Mousa SA, Petersen LJ (2009) Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost 102(2):258–267
13. Hirsh J (1991) Heparin. N Engl J Med 324(22):1565–1574
14. Barrowcliffe T (2012) History of heparin. Handb Exp Pharmacol 207:3–22
15. Bijsterveld N, Hettiarachchi R, Peters R, Prins M, Levi M, Büller H (1999) Low-molecular weight heparins in venous and arterial thrombotic disease. Thromb Haemost 82(Suppl 2):139–147
16. Petitou M, Casu B, Lindahl U (2003) 1976–1983, a critical period in the history of heparin: the discoveryof the antithrombin binding site. Biochimie 85(1):83–89
17. Gray E, Hogwood J, Mulloy B (2012) The anticoagulant and antithrombotic mechanisms of heparin. Handb Exp Pharmacol 207:43–61
18. Magnus N, Gerges N, Jabado N, Rak J (2013) Coagulation-related gene expression profile in glioblastoma is defined by molecular disease subtype. Thromb Haemost 11(6):1197–1200
19. Magnus N, D’Asti E, Meehan B, Garnier D, Rak J (2014) Oncogenes and the coagulation system-forces that modulate dormant and aggressive states in cancer. Thromb Res 133(Suppl):S1–S9
20. Sartori MT, Della Puppa A, Ballin A, Campello E, Radu CM, Saggiorato G, d’Avella D, Scienza R, Cella G, Simioni P (2013) Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role. Thromb Haemost 110(2):378–385
21. Lever R, Page CP (2012) Non-anticoagulant effects of heparin: an overview. Handb Exp Pharmacol 207:281–305
22. Oremus M, Hanson MD, Whitlock R, Young E, Archer C, Dal Cin A et al (2007) A systematic review of heparin to treat burn injury. J Burn Care Res 28(6):794–804
23. Smorenburg SM, van Noorden CJF (2001) The Complex Effects of Heparins on Cancer. Pharmacol Rev 53(1):93–105
24. Niers TMH, Klerk CPW, DiNisio M, Van Noorden CJF, Büller HR, Reitsma PH et al (2007) Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 61(3):195–207
25. Kargiotis O, Rao JS, Kyritsis AP (2006) Mechanisms of angiogenesis in gliomas. J Neurooncol 78(3):281–293
26. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8(8):610–622
27. Akaogi K, Okabe Y, Sato J, Nagashima Y, Yasumitsu H, Sugahara K (1996) Specific accumulation of tumor-derived adhesion factor in tumor blood vessels and in capillary tube-like structures of cultured vascular endothelial cells. Proc Natl Acad Sci USA 93(16):8384–8389
28. Christianson HC, van Kuppevelt TH, Belting M (2012) ScFv anti-heparan sulfate antibodies unexpectedly activate endothelial and cancer cells through p38 MAPK: implications for antibody-based targeting of heparan sulfate proteoglycans in cancer. PLoS ONE 7(11):e49092
29. Svensson KJ, Kucharzewska P, Christianson HC, Sköld S, Löfstedt T, Johansson MC et al (2011) Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. Proc Natl Acad Sci USA 108(32):13147–13152
30. Zhao P, Gao C, Dykema K, Furge K, Feng Z, Cao B (2010) Repeated hepatocyte growth factor neutralizing antibody treatment leads to HGF/SF unresponsiveness in human glioblastoma multiforme cells. Cancer Lett 291(2):209–216
31. Lund EL, Olsen MWB, Lipson KE, Mcmahon G, Howlett AR, Kristjansen PEG (2003) Improved Effect of an antiangiogenic tyrosine kinase inhibitor (su5416) by combinations with fractionated radiotherapy or low molecular weight heparin. Neoplasia 5(2):155–160
32. Brat DJ (2003) Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann Intern Med 138(8):659
33. Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang W-T, Nelson PT et al (2004) Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 10(24):8177–8184
34. Belting M, Ahamed J, Ruf W (2005) Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 25(8):1545–1550
35. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA et al (1997) Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57(23):5391–5398
36. Vajkoczy P, Menger MD, Vollmar B, Schilling L, Schmiedek P, Hirth KP et al (1999) Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1(1):31–41
37. D’Asti E, Garnier D, Lee TH, Montermini L, Meehan B, Rak J (2012) Oncogenic extracellular vesicles in brain tumor progression. Front Physiol 3:294
38. De Vrij J, Maas SL, Kwappenberg KM, Schnoor R, Kleijn A, Dekker L, Luider TM, de Witte LD, Litjens M, van Strien ME, Hol EM, Kroonen J, Robe PA, Lamfers ML, Schilham MW (2015) Broekman ML (2015) Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells. Int J Cancer. doi:10.1002/ijc.29521
39. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A et al (2008) Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 10(5):619–624
40. Christianson HC, Svensson KJ, Van Kuppevelt TH, Li J, Belting M (2013) Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. PNAS 110(43):17380–17385
41. Giese A, Westphal M (1996) Glioma invasion in the central nervous system. Neurosurgery 39(2):235–50; discussion 250–2
42. De Aguiar C, Lobão-Soares B, Alvarez-Silva M, Trentin AG (2005) Glycosaminoglycans modulate C6 glioma cell adhesion to extracellular matrix components and alter cell proliferation and cell migration. BMC Cell Biol 6:31
43. Balzarotti M, Fontana F, Marras C, Boiardi A, Croci D, Ciusani E et al (2006) In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas. Oncol Res 16(5):245–250
44. Okumura N, Takimoto K, Okada M, Nakagawa H (1989) C6 glioma cells produce basic fibroblast growth factor that can stimulate their own proliferation. J Biochem 106(5):904–909
45. Stukel JM, Caplan MR (2009) Targeted drug delivery for treatment and imaging of glioblastoma multiforme. Expert Opin Drug Deliv 6(7):705–718
46. Rudling MJ, Collins VP, Peterson CO, Pathway LL (1983) Delivery of aclacinomycin a to human glioma cells in vitro by the low-density lipoprotein pathway. Cancer Res 43:4600–4605
47. Goldstein JL, Basu SK, Brunschede GY, Brown MS (1976) Release of low density lipoprotein from its cell surface receptor by sulfated glycosaminoglycans. Cell 7(1):85–95
48. Maguire CA, Gianni D, Meijer DH, Shaket LA, Wakimoto H, Rabkin SD et al (2010) Directed evolution of adeno-associated virus for glioma cell transduction. J Neurooncol 96(3):337–347
49. Mietzsch M, Broecker F, Reinhardt A, Seeberger PH, Heilbronn R (2014) Differential adeno-associated virus serotype-specific interaction patterns with synthetic heparins and other glycans. J Virol 88(5):2991–3003
50. Robins HI, O’Neill A, Gilbert M, Olsen M, Sapiente R, Berkey B et al (2008) Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. Cancer Chemother Pharmacol 62(2):227–233
51. Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR et al (2010) PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 8(9):1959–1965
52. Zincircioglu SB, Kaplan MA, Isikdogan A, Cil T, Karadayi B, Dirier A et al (2012) Contribution of low-molecular weight heparin addition to concomitant chemo- radiotherapy in the treatment of glioblastoma multiforme. J Balk Union Oncol 17:124–127
53. Che DH, Cao JY, Shang LH, Man YC, Yu Y (2013) The efficacy and safety of low-molecular-weight heparin use for cancer treatment: a meta-analysis. Eur J Intern Med 24(5):433–439
54. Kuderer NM, Ortel TL, Francis CW (2009) Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 27(29):4902–4911
55. Sanford D, Naidu A, Alizadeh N, Lazo-Langner A (2014) The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials. J Thromb Haemost 12(7):1076–1085
56. Lazo-Langner A, Goss G, Spaans J, Rodger M (2007) The effect of low- molecular-weight heparin on cancer survival. A systematic review and meta- analysis of randomized trials. J Thromb Haemost 5:729–737
57. Chen J-L, Fan J, Chen M-X, Dong Y, Gu J-Z (2012) Effect of non-anticoagulant N-desulfated heparin on basic fibroblast growth factor expression, angiogenesis, and metastasis of gastric carcinoma in vitro and in vivo. Gastroenterol Res Pract 2012:752940
58. Mousa SA, Linhardt R, Francis JL, Amirkhosravi A (2006) Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost 96(6):816–821
59. Sudha T, Yalcin M, Lin H-Y, Elmetwally AM, Nazeer T, Arumugam T et al (2014) Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin. Cancer Lett 350(1–2):25–33
60. Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, Duffner J et al (2011) M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS ONE 6(6):e21106